BMY
Price
$49.29
Change
+$0.21 (+0.43%)
Updated
Nov 13, 03:27 PM (EDT)
Capitalization
99.91B
84 days until earnings call
Intraday BUY SELL Signals
PFE
Price
$25.80
Change
-$0.07 (-0.27%)
Updated
Nov 13, 04:00 PM (EDT)
Capitalization
147.09B
82 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BMY vs PFE

Header iconBMY vs PFE Comparison
Open Charts BMY vs PFEBanner chart's image
Bristol-Myers Squibb
Price$49.29
Change+$0.21 (+0.43%)
Volume$12.68K
Capitalization99.91B
Pfizer
Price$25.80
Change-$0.07 (-0.27%)
Volume$285.66K
Capitalization147.09B
BMY vs PFE Comparison Chart in %
View a ticker or compare two or three
VS
BMY vs. PFE commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Buy and PFE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (BMY: $49.08 vs. PFE: $25.87)
Brand notoriety: BMY and PFE are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BMY: 82% vs. PFE: 136%
Market capitalization -- BMY: $99.91B vs. PFE: $147.09B
BMY [@Pharmaceuticals: Major] is valued at $99.91B. PFE’s [@Pharmaceuticals: Major] market capitalization is $147.09B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $910.93B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $98.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMY’s FA Score shows that 2 FA rating(s) are green whilePFE’s FA Score has 2 green FA rating(s).

  • BMY’s FA Score: 2 green, 3 red.
  • PFE’s FA Score: 2 green, 3 red.
According to our system of comparison, BMY is a better buy in the long-term than PFE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMY’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 5 bullish TA indicator(s).

  • BMY’s TA Score: 5 bullish, 5 bearish.
  • PFE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both BMY and PFE are a bad buy in the short-term.

Price Growth

BMY (@Pharmaceuticals: Major) experienced а +5.62% price change this week, while PFE (@Pharmaceuticals: Major) price change was +6.97% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.48%. For the same industry, the average monthly price growth was +1.46%, and the average quarterly price growth was +19.41%.

Reported Earning Dates

BMY is expected to report earnings on Feb 05, 2026.

PFE is expected to report earnings on Feb 03, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+3.48% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PFE($147B) has a higher market cap than BMY($99.9B). BMY has higher P/E ratio than PFE: BMY (16.53) vs PFE (15.04). PFE YTD gains are higher at: 4.568 vs. BMY (-8.912). PFE has higher annual earnings (EBITDA): 18.5B vs. BMY (15.1B). BMY has less debt than PFE: BMY (50.9B) vs PFE (60.9B). PFE has higher revenues than BMY: PFE (62.8B) vs BMY (47.7B).
BMYPFEBMY / PFE
Capitalization99.9B147B68%
EBITDA15.1B18.5B82%
Gain YTD-8.9124.568-195%
P/E Ratio16.5315.04110%
Revenue47.7B62.8B76%
Total CashN/AN/A-
Total Debt50.9B60.9B84%
FUNDAMENTALS RATINGS
BMY vs PFE: Fundamental Ratings
BMY
PFE
OUTLOOK RATING
1..100
1319
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
33100
PRICE GROWTH RATING
1..100
5033
P/E GROWTH RATING
1..100
5496
SEASONALITY SCORE
1..100
985

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (4) in the Pharmaceuticals Major industry is in the same range as PFE (32). This means that BMY’s stock grew similarly to PFE’s over the last 12 months.

BMY's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PFE (100). This means that BMY’s stock grew similarly to PFE’s over the last 12 months.

BMY's SMR Rating (33) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that BMY’s stock grew significantly faster than PFE’s over the last 12 months.

PFE's Price Growth Rating (33) in the Pharmaceuticals Major industry is in the same range as BMY (50). This means that PFE’s stock grew similarly to BMY’s over the last 12 months.

BMY's P/E Growth Rating (54) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (96). This means that BMY’s stock grew somewhat faster than PFE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMYPFE
RSI
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
49%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
49%
Momentum
ODDS (%)
Bullish Trend 2 days ago
43%
Bullish Trend 2 days ago
43%
MACD
ODDS (%)
Bullish Trend 2 days ago
52%
Bullish Trend 2 days ago
44%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
50%
Bullish Trend 2 days ago
56%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
51%
Bullish Trend 2 days ago
51%
Advances
ODDS (%)
Bullish Trend 2 days ago
52%
Bullish Trend 2 days ago
56%
Declines
ODDS (%)
Bearish Trend 10 days ago
54%
Bearish Trend 22 days ago
59%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
52%
Aroon
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 2 days ago
57%
View a ticker or compare two or three
Interact to see
Advertisement
BMY
Daily Signal:
Gain/Loss:
PFE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NVOX2.800.13
+4.87%
Defiance Daily Target 2X Long NVO ETF
KRBN34.130.32
+0.95%
KraneShares Global Carbon ETF
VFH130.751.13
+0.87%
Vanguard Financials ETF
AOK40.770.24
+0.60%
iShares Core 30/70 Cnsrv Allc ETF
RMIF24.96N/A
N/A
LHA Risk-Managed Income ETF

BMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
+0.74%
PFE - BMY
60%
Loosely correlated
+1.41%
BIIB - BMY
53%
Loosely correlated
+1.20%
MRK - BMY
52%
Loosely correlated
+0.55%
AMGN - BMY
51%
Loosely correlated
-0.64%
NVS - BMY
51%
Loosely correlated
+1.37%
More

PFE and

Correlation & Price change

A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BIIB. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BIIB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PFE
1D Price
Change %
PFE100%
+1.41%
BIIB - PFE
65%
Loosely correlated
+1.20%
AMGN - PFE
63%
Loosely correlated
-0.64%
BMY - PFE
60%
Loosely correlated
+0.74%
NVS - PFE
60%
Loosely correlated
+1.37%
AZN - PFE
59%
Loosely correlated
-1.58%
More